on Biophytis (EPA:ALBPS)
Biophytis to Attend BIO-Europe Spring 2025 in Milan
Biophytis, a clinical-stage biotech company, is set to participate in the BIO-Europe Spring 2025 event in Milan from March 17 to 19. The company, known for developing treatments for age-related diseases, aims to exchange insights with industry leaders on its leading drug candidate, BIO101. This compound is being developed for conditions such as obesity and sarcopenia, with various phases of trials underway.
During the event, Edouard Bieth, Chief Business Officer of Biophytis, will be engaging in numerous meetings. The conference is a major European gathering for pharmaceutical professionals, providing a platform for networking and discussion on innovative solutions in biotechnology.
The company's presence highlights its commitment to advancing research and collaboration within the industry. Biophytis operates globally, with key locations in France, the USA, and Brazil.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news